Back

TRIB1 modulates transcriptional programming in breast cancer cells to regulate cell proliferation

McMillan, H. D.; Papachristou, E. K.; Hazlett, J.; Omarjee, S.; Carroll, J.; Black, M.; Mace, P. D.; Dunbier, A.

2023-07-07 cancer biology
10.1101/2023.07.06.547928 bioRxiv
Show abstract

The pseudokinase Tribbles Homolog 1 (TRIB1) is a known driver of tumorigenesis in acute myeloid leukemia and is encoded upstream of the oncogene MYC at the 8q24 locus. We observed that TRIB1/MYC co-amplification is associated with decreased relapse-free and overall survival in breast cancer patients, but the role of TRIB1 in this disease has not been well characterized. TRIB1 knockdown in multiple breast cancer cell lines inhibited cell proliferation and suppressed MYC expression, implicating TRIB1 in breast cancer cell proliferation. Transcriptomic and cell cycle analysis revealed cell cycle regulation as the likely mechanism through which TRIB1 influences breast cancer cell proliferation. TRIB1 knockdown also resulted in significant changes in both estrogen receptor (ER) and {beta}-catenin associated transcription. Interrogating the TRIB1 interactome in breast cancer cells by qPLEX-RIME reinforced the known association between TRIB1 and ubiquitination, while revealing a range of previously undescribed TRIB1 associated factors. Further analysis of the association between TRIB1, {beta}-catenin and FERMT2 suggests TRIB1 may regulate {beta}-catenin activity by controlling the levels of both {beta}-catenin, and its co-factor FERMT2. Together, these results suggest that coregulation of {beta}-catenin and ER-driven transcription by TRIB1, facilitates regulation of MYC expression and breast cancer cell proliferation. SignificanceThe pseudokinase TRIB1 is frequently co-amplified in breast cancers with the potent oncogene MYC, although the functional consequences of this event are not well understood. This study demonstrates TRIB1 is a regulator of cell cycle progression and MYC expression in breast cancer cells. It also profiles TRIB1-associated proteins in breast cancer cells, demonstrating conservation of TRIB1s canonical interaction with COP1 and reveals associations with members of the wider ubiquitination machinery, a range of transcriptional regulators and chromatin remodelers. The data presented provide insight into the function of TRIB1 in breast cancer and the role of TRIB1 in transcriptional regulation.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
Molecular Cancer Research
42 papers in training set
Top 0.1%
22.5%
2
Breast Cancer Research
32 papers in training set
Top 0.1%
8.4%
3
Oncogene
76 papers in training set
Top 0.2%
6.4%
4
Cell Reports
1338 papers in training set
Top 7%
6.3%
5
Scientific Reports
3102 papers in training set
Top 24%
4.8%
6
Cancer Research
116 papers in training set
Top 0.4%
4.8%
50% of probability mass above
7
PLOS Genetics
756 papers in training set
Top 3%
4.3%
8
PLOS ONE
4510 papers in training set
Top 36%
4.0%
9
Cancers
200 papers in training set
Top 2%
3.7%
10
eLife
5422 papers in training set
Top 32%
2.6%
11
Cell Communication and Signaling
35 papers in training set
Top 0.3%
2.1%
12
PLOS Computational Biology
1633 papers in training set
Top 15%
1.9%
13
Nucleic Acids Research
1128 papers in training set
Top 9%
1.9%
14
Molecular Biology of the Cell
272 papers in training set
Top 1%
1.8%
15
Nature Communications
4913 papers in training set
Top 52%
1.7%
16
Communications Biology
886 papers in training set
Top 10%
1.7%
17
iScience
1063 papers in training set
Top 25%
0.9%
18
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 41%
0.9%
19
Cancer Research Communications
46 papers in training set
Top 1%
0.7%
20
Cell Genomics
162 papers in training set
Top 6%
0.7%
21
Clinical Cancer Research
58 papers in training set
Top 2%
0.7%
22
BMC Cancer
52 papers in training set
Top 3%
0.7%
23
npj Breast Cancer
18 papers in training set
Top 0.2%
0.7%
24
PeerJ
261 papers in training set
Top 18%
0.6%
25
Developmental Cell
168 papers in training set
Top 13%
0.6%